The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applications, coupled with the introduction of theranostics, has opened up opportunities for companies having capabilities to manufacture nuclear medicine and radiopharmaceuticals
Roots Analysis is pleased to announce the publication of its recent study, titled, “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030”
The report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:
- A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals.
- An insightful four-dimensional comparison of the radiopharmaceutical manufacturers.
- Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players).
- An analysis of recent partnerships and collaborations inked in this domain since 2017.
- A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m).
Key Market Insights
- Close to 130 industry and non-industry players, across the globe, claim to have the necessary expertise and supporting infrastructure to manufacture a wide variety of radioisotopes, for in-house use, or as a contract service
- The market is fragmented, featuring the presence of companies in both developed and developing nations, which are capable of manufacturing radiopharmaceuticals for various applications at different scales of production
- The growing interest in this field is reflected in the yearly growth in partnership activity; the majority of deals inked in the recent past include manufacturing and supply agreements for various types of radiopharmaceuticals
- Stakeholders are actively expanding their capabilities in order to enhance their respective nuclear medicine and radiopharmaceutical manufacturing capabilities and, thereby, maintain a competitive edge in this industry
- Case Study: The decay product of Mo-99, Tc-99m, is used in majority of the radioactivity-based diagnostic applications in the US; reactors in the European region alone contribute to 60% of the global production capacity
- In the long-term, the forecasted opportunity is anticipated to be higher for radioisotopes intended for diagnostic applications, mostly for use in the field of cardiology, with North America holding the dominant position
SPECT and beta-emitters are anticipated to generate the majority share of revenues across diagnostic and therapeutic applications, respectively, for both in-house use and radiopharmaceutical supply contracts
Request for Customization:
Also Visit Our Latest Publication
This post was created with our nice and easy submission form. Create your post!